M&A: Page 15
-
Dollar Photo Club
Exact Sciences-Guardant rivalry in colorectal testing market heats up
Exact bolstered its play for the residual disease and recurrence segment by striking a deal to buy Ashion Analytics, while Guardant disclosed availability of its liquid biopsy test for the same market.
By Nick Paul Taylor • Feb. 17, 2021 -
Courtesy of Qiagen
Qiagen shuns M&A that 'dilutes' its focus amid reports of Quidel merger
Qiagen’s CEO said his business development team is focused on bolt-on acquisitions that support and strengthen its operations in five target areas.
By Nick Paul Taylor • Feb. 10, 2021 -
Permission granted by Quidel Corporation
Report of Quidel-Qiagen tie-up makes 'no sense,' Wall Street analysts say
Bloomberg reported the two companies are in early discussions. But while one analyst said it was a "plausible, though far-fetched" combination to create a global diagnostics firm, several questioned the wisdom of a union.
By Greg Slabodkin • Feb. 9, 2021 -
Zimmer takes electives hit in Q4, to spin off spine, dental units
"There's just no doubt that COVID, unfortunately, remains a challenge ... We're seeing the pandemic pressure and the surges continue and, frankly, worsen across pretty much all of our regions and markets," said CEO Bryan Hanson.
By Ricky Zipp • Feb. 5, 2021 -
PerkinElmer predicts sharp falloff in COVID-19 sales this year
In a relatively rare admission by a testing company, execs said they expect around 50% of 2021 coronavirus sales to come in the first quarter, beyond which vaccines are tipped to drive down demand.
By Nick Paul Taylor • Feb. 3, 2021 -
Fotolia
Deep Dive3 big predictions for digital health in 2021
As tech and data sharing become more pervasive, healthcare will likely pivot to being more predictive and telehealth will evolve, giving rise to new modalities of care. This will force companies to invest more in cybersecurity.
By Rebecca Pifer • Jan. 29, 2021 -
Philips beats Q4 expectations as COVID-19 boosts connected care, slows procedures
The Dutch conglomerate will continue to be active on the M&A front, CEO Frans van Houten told investors, after striking two deals in the space over the past month worth more than $3.4 billion.
By Nick Paul Taylor • Jan. 25, 2021 -
Boston Scientific bets on cardiac wearables with $925M Preventice buy
The deal is the latest in the fast-growing space, coming on the heels of Hillrom's $375 million BardyDx buy on Tuesday and Philips' $2.8 billion purchase of BioTelemetry last month.
By Ricky Zipp • Jan. 21, 2021 -
Adobe Stock
Haemonetics inks $510M Cardiva takeover to expand hospital business
The blood products medtech contends the deal will strengthen its portfolio in interventional cardiology and electrophysiology markets.
By Nick Paul Taylor • Jan. 21, 2021 -
Adobe Stock
Hillrom makes cardiac monitoring play with $375M BardyDx buy
The deal fits Hillrom's existing heart portfolio and efforts to connect devices to the internet, analysts said, but one raised concerns about Medicare reimbursement.
By Susan Kelly • Jan. 20, 2021 -
Thermo Fisher buys Mesa Biotech for $450M to bolster rapid point-of-care testing
The all-cash acquisition, which includes the potential for an additional $100 million upon completion of milestones, adds Mesa's PCR test platform for SARS-CoV-2, influenza A and B, RSV and strep A to Thermo's portfolio.
By Greg Slabodkin • Jan. 19, 2021 -
Philips to acquire Capsule Technologies in $635M deal, growing patient data capabilities
The move follows the medtech giant's $2.8 billion acquisition of cardiac monitoring company BioTelemetry in December, one of 2020's largest deals.
By Ricky Zipp • Jan. 19, 2021 -
Yujin Kim/MedTech Dive
Pandemic propels health systems to mull insurer acquisitions, partnerships: JPM21
Advocate Aurora CEO Jim Skogsbergh said "partnering for health plan capability is going to be critical to our success."
By Samantha Liss • Jan. 14, 2021 -
Steris inks $4.6B buy of Cantel Medical amid flurry of M&A
It's the biggest deal so far this year. Wall Street analysts said COVID-19 infection concerns should boost Cantel in the long term.
By Ricky Zipp • Jan. 13, 2021 -
Adobe Stock
Healthcare CFOs see fresh wave of M&A in 2021: BDO poll
Financial distress, a desire to expand into new service lines and efforts to close infrastructure gaps are expected to fuel the upturn, according to the consultants.
By Susan Kelly • Jan. 12, 2021 -
Fotolia
Medtech M&A to take off after pandemic slowed deals in 2020: EY
Dealmaking in 2021 will be fueled by financial firepower across the industry at an "all-time high" of nearly $500 billion, according to the consultants.
By Ricky Zipp • Jan. 10, 2021 -
PerkinElmer inks $591M Oxford Immunotec buy to challenge Qiagen in TB market
The deal comes amid a flurry of medtech M&A during the first week of 2021. Hologic inked two acquisitions in the women's health space and Stryker said it would buy sensor maker OrthoSensor.
By Nick Paul Taylor • Jan. 8, 2021 -
Hologic's $230M Biotheranostics buy its 2nd M&A deal of 2021
Some Wall Street analysts were surprised by the target, but others suggested the move could strengthen the company for a post-coronavirus environment.
By Ricky Zipp • Jan. 6, 2021 -
Photo courtesy of Stryker
Stryker buys sensor maker in bet on wearables in orthopaedics
OrthoSensor's technology could complement the medtech's robotics platform and boost its data analytics capabilities, SVB Leerink analysts said in a Tuesday note on the acquisition.
By Susan Kelly • Jan. 5, 2021 -
Hologic eyes future post COVID-19 with Somatex Medical tuck-in
The medical device maker is bulking up its women's health business as molecular diagnostics sales surge due to the pandemic. Wall Street analysts have said these lines are equipped to withstand market uncertainties.
By Susan Kelly • Jan. 5, 2021 -
Adobe Stock
The top medtech deals of 2020 (and one that got away)
M&A activity bounced back in the second half of the year, with deals ranging from Teladoc's $18.5 billion Livongo buy to Stryker's drawn-out $4 billion acquisition of Wright Medical.
By Susan Kelly • Jan. 4, 2021 -
Getty / edited by Healthcare Dive
Hospital giant Tenet goes big on ASCs
A shift in focus to outpatient settings is also occurring among medical device companies. Both Stryker and Zimmer Biomet have made ASCs more of a priority over the last several years.
By Samantha Liss • Dec. 22, 2020 -
Philips buys cardiac monitoring company BioTelemetry in $2.8B deal
The Dutch conglomerate said that the move will expand its remote patient monitoring business beyond the hospital space. Baird called the pact a surprise but the valuation fair.
By Ricky Zipp • Dec. 18, 2020 -
Olympus to pay $300M to buy Veran for lung navigation system
The deal is for $300 million up front, with another $40 million tied to an undisclosed milestone.
By Nick Paul Taylor • Dec. 7, 2020 -
Courtesy of LivaNova/Businesswire
LivaNova offloads heart valve tech to Gyrus Capital following investor pressure
The announcement comes shortly after activist shareholder PrimeStone Capital demanded LivaNova sell or close the "likely loss-making" business line.
By Maria Rachal • Dec. 3, 2020
Previous
